

Marie Louise De Bruin

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2011037/marie-louise-de-bruin-publications-by-year.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

127
papers

4,866
citations

33
h-index

67
g-index

136
ext. papers

5,648
ext. citations

5
avg. IF

5.23
L-index

#	Paper	IF	Citations
127	Interchangeability of biosimilars: A study of expert views and visions regarding the science and substitution.. <i>PLoS ONE</i> , 2022 , 17, e0262537	3.7	0
126	Guidance for pediatric use in prescription information for novel medicinal products in the EU and the US.. <i>PLoS ONE</i> , 2022 , 17, e0266353	3.7	0
125	Hydroxyzine Initiation Following Drug Safety Advisories on Cardiac Arrhythmias in the UK and Canada: A Longitudinal Cohort Study.. <i>Drug Safety</i> , 2022 , 1	5.1	1
124	Use of Real-World Data and Evidence in Drug Development of Medicinal Products Centrally Authorized in Europe in 2018-2019. <i>Clinical Pharmacology and Therapeutics</i> , 2021 , 111, 310	6.1	2
123	Regulatory density as a means to refine current regulatory approaches for increasingly complex medicines. <i>Drug Discovery Today</i> , 2021 , 26, 2221-2225	8.8	1
122	Evolving Biosimilar Clinical Requirements: A Qualitative Interview Study with Industry Experts and European National Medicines Agency Regulators. <i>BioDrugs</i> , 2021 , 35, 351-361	7.9	
121	Comparing risk of major bleeding between users of different oral anticoagulants in patients with nonvalvular atrial fibrillation. <i>British Journal of Clinical Pharmacology</i> , 2021 , 87, 988-1000	3.8	3
120	Postmarket Safety Communication for Protection of Public Health: A Comparison of Regulatory Policy in Australia, Canada, the European Union, and the United States. <i>Clinical Pharmacology and Therapeutics</i> , 2021 , 109, 1424-1442	6.1	3
119	Prescribers' compliance with summary of product characteristics of dabigatran, rivaroxaban and apixaban-A European comparative drug utilization study. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2021 , 128, 440-454	3.1	1
118	Major bleeding in users of direct oral anticoagulants in atrial fibrillation: A pooled analysis of results from multiple population-based cohort studies. <i>Pharmacoepidemiology and Drug Safety</i> , 2021 , 30, 1339-1352	2.6	4
117	A cross-sectional survey of knowledge pertaining to IV fluid therapy and hyponatraemia among nurses working at emergency departments in Denmark. <i>International Emergency Nursing</i> , 2021 , 57, 1010104	2.4	
116	Scenarios for 3D printing of personalized medicines - A case study.. <i>Exploratory Research in Clinical and Social Pharmacy</i> , 2021 , 4, 100073		5
115	Surveillance of Antidepressant Safety (SADS): Active Signal Detection of Serious Medical Events Following SSRI and SNRI Initiation Using Big Healthcare Data. <i>Drug Safety</i> , 2021 , 44, 1215-1230	5.1	0
114	Poor adherence and persistence to sodium glucose co-transporter 2 inhibitors in real-world settings: Evidence from a systematic review and meta-analysis. <i>Diabetes/Metabolism Research and Reviews</i> , 2021 , 37, e3350	7.5	3
113	Improving Interactions Between Health Technology Assessment Bodies and Regulatory Agencies: A Systematic Review and Cross-Sectional Survey on Processes, Progress, Outcomes, and Challenges. <i>Frontiers in Medicine</i> , 2020 , 7, 582634	4.9	1
112	A qualitative study of biosimilar manufacturer and regulator perceptions on intellectual property and abbreviated approval pathways. <i>Nature Biotechnology</i> , 2020 , 38, 1253-1256	44.5	6
111	Publication rates and reported results in a cohort of gene- and cell-based therapy trials. <i>Regenerative Medicine</i> , 2020 , 15, 1215-1227	2.5	1

110	Pharmacogenetic-Pharmacokinetic Interactions in Drug Marketing Authorization Applications via the European Medicines Agency Between 2014 and 2017. <i>Clinical Pharmacology and Therapeutics</i> , 2020 , 108, 338-349	6.1	1
109	Regulating advanced therapy medicinal products through the Hospital Exemption: an analysis of regulatory approaches in nine EU countries. <i>Regenerative Medicine</i> , 2020 , 15, 2015-2028	2.5	1
108	Cancer is associated with severe disease in COVID-19 patients: a systematic review and meta-analysis. <i>Ecancermedicalscience</i> , 2020 , 14, 1047	2.7	16
107	Advanced therapy medicinal product manufacturing under the hospital exemption and other exemption pathways in seven European Union countries. <i>Cytotherapy</i> , 2020 , 22, 592-600	4.8	4
106	Are monitoring instructions provided in direct healthcare professional communications (DHPCs) of sufficient quality? A retrospective analysis of DHPCs sent out between 2007 and 2018. <i>BMJ Open</i> , 2020 , 10, e036498	3	6
105	Are Further Interventions Needed to Prevent and Manage Hospital-Acquired Hyponatraemia? A Nationwide Cross-Sectional Survey of IV Fluid Prescribing Practices. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	2
104	Body of evidence and approaches applied in the clinical development programme of fixed-dose combinations in the European Union from 2010 to 2016. <i>British Journal of Clinical Pharmacology</i> , 2019 , 85, 1829-1840	3.8	4
103	Adjusting for unmeasured confounding using validation data: Simplified two-stage calibration for survival and dichotomous outcomes. <i>Statistics in Medicine</i> , 2019 , 38, 2719-2734	2.3	1
102	The effectiveness of direct to healthcare professional communication - A systematic review of communication factor studies. <i>Research in Social and Administrative Pharmacy</i> , 2019 , 15, 475-482	2.9	8
101	Postauthorization Changes to Specific Obligations of Conditionally Authorized Medicines in the European Union: A Retrospective Cohort Study. <i>Clinical Pharmacology and Therapeutics</i> , 2019 , 105, 426-435	6.1	6
100	Incidence of direct oral anticoagulant use in patients with nonvalvular atrial fibrillation and characteristics of users in 6 European countries (2008-2015): A cross-national drug utilization study. <i>British Journal of Clinical Pharmacology</i> , 2019 , 85, 2524-2539	3.8	29
99	Genetic susceptibility to radiation-induced breast cancer after Hodgkin lymphoma. <i>Blood</i> , 2019 , 133, 1130-1139	2.2	17
98	A decade of marketing approval of gene and cell-based therapies in the United States, European Union and Japan: An evaluation of regulatory decision-making. <i>Cytotherapy</i> , 2018 , 20, 769-778	4.8	13
97	EU decision-making for marketing authorization of advanced therapy medicinal products: a case study. <i>Drug Discovery Today</i> , 2018 , 23, 1328-1333	8.8	17
96	Global Regulatory Differences for Gene- and Cell-Based Therapies: Consequences and Implications for Patient Access and Therapeutic Innovation. <i>Clinical Pharmacology and Therapeutics</i> , 2018 , 103, 120-127	6.1	15
95	When More Is Less: An Exploratory Study of the Precautionary Reporting Bias and Its Impact on Safety Signal Detection. <i>Clinical Pharmacology and Therapeutics</i> , 2018 , 103, 296-303	6.1	14
94	The association of diabetes mellitus and insulin treatment with expression of insulin-related proteins in breast tumors. <i>BMC Cancer</i> , 2018 , 18, 224	4.8	6
93	Gastrointestinal cancer incidence in type 2 diabetes mellitus; results from a large population-based cohort study in the UK. <i>Cancer Epidemiology</i> , 2018 , 54, 104-111	2.8	14

92	Trends in breast cancer incidence among women with type-2 diabetes in British general practice. <i>Primary Care Diabetes</i> , 2017 , 11, 373-382	2.4	7
91	Registries in European post-marketing surveillance: a retrospective analysis of centrally approved products, 2005-2013. <i>Pharmacoepidemiology and Drug Safety</i> , 2017 , 26, 1442-1450	2.6	25
90	Infradiaphragmatic irradiation and high procarbazine doses increase colorectal cancer risk in Hodgkin lymphoma survivors. <i>British Journal of Cancer</i> , 2017 , 117, 306-314	8.7	16
89	Cancer risk among insulin users: comparing analogues with human insulin in the CARING five-country cohort study. <i>Diabetologia</i> , 2017 , 60, 1691-1703	10.3	41
88	Diabetes and Breast Cancer Subtypes. <i>PLoS ONE</i> , 2017 , 12, e0170084	3.7	29
87	Evidence Synthesis in Harm Assessment of Medicines Using the Example of Rosiglitazone and Myocardial Infarction. <i>Frontiers in Medicine</i> , 2017 , 4, 228	4.9	1
86	Breast Cancer Risk After Radiation Therapy for Hodgkin Lymphoma: Influence of Gonadal Hormone Exposure. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017 , 99, 843-853	4	22
85	Lessons learned on the design and the conduct of Post-Authorization Safety Studies: review of 3 years of PRAC oversight. <i>British Journal of Clinical Pharmacology</i> , 2017 , 83, 884-893	3.8	29
84	Use of incretin agents and risk of acute and chronic pancreatitis: A population-based cohort study. <i>Diabetes, Obesity and Metabolism</i> , 2017 , 19, 401-411	6.7	15
83	Ankylosing spondylitis and risk of ischaemic heart disease: a population-based cohort study. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 203-9	2.4	54
82	Calcium channel blockers and cancer: a risk analysis using the UK Clinical Practice Research Datalink (CPRD). <i>BMJ Open</i> , 2016 , 6, e009147	3	34
81	Adverse Drug Reaction Reporting in Africa and a Comparison of Individual Case Safety Report Characteristics Between Africa and the Rest of the World: Analyses of Spontaneous Reports in VigiBase. <i>Drug Safety</i> , 2016 , 39, 335-45	5.1	75
80	Use of incretin agents and risk of pancreatic cancer: a population-based cohort study. <i>Diabetes, Obesity and Metabolism</i> , 2016 , 18, 258-65	6.7	21
79	Traceability of Biologics in The Netherlands: An Analysis of Information-Recording Systems in Clinical Practice and Spontaneous ADR Reports. <i>Drug Safety</i> , 2016 , 39, 185-92	5.1	26
78	The effect of exposure misclassification in spontaneous ADR reports on the time to detection of product-specific risks for biologicals: a simulation study. <i>Pharmacoepidemiology and Drug Safety</i> , 2016 , 25, 297-306	2.6	7
77	Benefit-risk reassessment of medicines: a retrospective analysis of all safety-related referral procedures in Europe during 2001-2012. <i>Pharmacoepidemiology and Drug Safety</i> , 2016 , 25, 1004-14	2.6	5
76	Characteristics and follow-up of postmarketing studies of conditionally authorized medicines in the EU. <i>British Journal of Clinical Pharmacology</i> , 2016 , 82, 213-26	3.8	31
75	Insulin glargine use and breast cancer risk: Associations with cumulative exposure. <i>Acta Oncologica</i> , 2016 , 55, 851-8	3.2	10

74	The risk of acute liver injury associated with the use of antibiotics--evaluating robustness of results in the pharmacoepidemiological research on outcomes of therapeutics by a European consortium (PROTECT) project. <i>Pharmacoepidemiology and Drug Safety</i> , 2016 , 25 Suppl 1, 47-55	2.6	7
73	Understanding inconsistency in the results from observational pharmacoepidemiological studies: the case of antidepressant use and risk of hip/femur fractures. <i>Pharmacoepidemiology and Drug Safety</i> , 2016 , 25 Suppl 1, 88-102	2.6	21
72	Validity of diagnostic codes and laboratory measurements to identify patients with idiopathic acute liver injury in a hospital database. <i>Pharmacoepidemiology and Drug Safety</i> , 2016 , 25 Suppl 1, 21-8	2.6	11
71	Exposure to benzodiazepines (anxiolytics, hypnotics and related drugs) in seven European electronic healthcare databases: a cross-national descriptive study from the PROTECT-EU Project. <i>Pharmacoepidemiology and Drug Safety</i> , 2016 , 25 Suppl 1, 56-65	2.6	73
70	The IMI PROTECT project: purpose, organizational structure, and procedures. <i>Pharmacoepidemiology and Drug Safety</i> , 2016 , 25 Suppl 1, 5-10	2.6	17
69	Multi-centre, multi-database studies with common protocols: lessons learnt from the IMI PROTECT project. <i>Pharmacoepidemiology and Drug Safety</i> , 2016 , 25 Suppl 1, 156-65	2.6	33
68	Epidemiology of adverse drug reactions in Europe: a review of recent observational studies. <i>Drug Safety</i> , 2015 , 38, 437-53	5.1	204
67	An analysis of marketing authorisation applications via the mutual recognition and decentralised procedures in Europe. <i>European Journal of Clinical Pharmacology</i> , 2015 , 71, 1237-44	2.8	7
66	Influence of metformin intake on the risk of bladder cancer in type 2 diabetes patients. <i>British Journal of Clinical Pharmacology</i> , 2015 , 80, 1464-72	3.8	15
65	Traceability of biologicals: present challenges in pharmacovigilance. <i>Expert Opinion on Drug Safety</i> , 2015 , 14, 63-72	4.1	35
64	Data management and data analysis techniques in pharmacoepidemiological studies using a pre-planned multi-database approach: a systematic literature review. <i>Pharmacoepidemiology and Drug Safety</i> , 2015 , 24, 897-905	2.6	15
63	Drug-induced progressive multifocal leukoencephalopathy: Lessons learned from contrasting natalizumab and rituximab. <i>Clinical Pharmacology and Therapeutics</i> , 2015 , 98, 542-50	6.1	17
62	Strategy in Regulatory Decision-Making for Management of Progressive Multifocal Leukoencephalopathy. <i>Clinical Pharmacology and Therapeutics</i> , 2015 , 98, 502-5	6.1	3
61	Are ECG monitoring recommendations before prescription of QT-prolonging drugs applied in daily practice? The example of haloperidol. <i>Pharmacoepidemiology and Drug Safety</i> , 2015 , 24, 701-8	2.6	21
60	Use of the conditional marketing authorization pathway for oncology medicines in Europe. <i>Clinical Pharmacology and Therapeutics</i> , 2015 , 98, 534-41	6.1	35
59	The epidemiology of extra-articular manifestations in ankylosing spondylitis: a population-based matched cohort study. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 1373-8	2.4	89
58	Risk of bladder cancer in patients with diabetes: a retrospective cohort study. <i>BMJ Open</i> , 2015 , 5, e007430		14
57	Treatment with insulin (analogues) and breast cancer risk in diabetics; a systematic review and meta-analysis of in vitro, animal and human evidence. <i>Breast Cancer Research</i> , 2015 , 17, 100	8.3	35

56	Classification of Recombinant Biologics in the EU: Divergence Between National Pharmacovigilance Centers. <i>BioDrugs</i> , 2015 , 29, 373-9	7.9	4
55	The risk of colorectal cancer in patients with type 2 diabetes: associations with treatment stage and obesity. <i>Diabetes Care</i> , 2015 , 38, 495-502	14.6	94
54	Long-term use of 5 α -reductase inhibitors and the risk of male breast cancer. <i>Cancer Causes and Control</i> , 2014 , 25, 1577-82	2.8	24
53	The Costs and Effects of Post-Authorisation Safety Studies For New Active Substances. <i>Value in Health</i> , 2014 , 17, A445-6	3.3	
52	Safety information on QT-interval prolongation: comparison of European Union and United States drug labeling. <i>Drug Discovery Today</i> , 2014 , 19, 1294-7	8.8	4
51	Incidence rates and trends of hip/femur fractures in five European countries: comparison using e-healthcare records databases. <i>Calcified Tissue International</i> , 2014 , 94, 580-9	3.9	36
50	Antidepressant prescribing in five European countries: application of common definitions to assess the prevalence, clinical observations, and methodological implications. <i>European Journal of Clinical Pharmacology</i> , 2014 , 70, 849-57	2.8	110
49	THU0090 Cardiovascular Morbidity in Patients with Ankylosing Spondylitis: A Population-Based Cohort Study. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 207.3-208	2.4	1
48	Risk management plans as a tool for proactive pharmacovigilance: a cohort study of newly approved drugs in Europe. <i>Clinical Pharmacology and Therapeutics</i> , 2014 , 96, 723-31	6.1	25
47	Resting heart rate is a risk factor for mortality in chronic obstructive pulmonary disease, but not for exacerbations or pneumonia. <i>PLoS ONE</i> , 2014 , 9, e105152	3.7	16
46	Quality of drug label information on QT interval prolongation. <i>International Journal of Risk and Safety in Medicine</i> , 2014 , 26, 89-98	1.6	5
45	Genetic, clinical and pharmacological determinants of out-of-hospital cardiac arrest: rationale and outline of the AmsteRdam Resuscitation Studies (ARREST) registry. <i>Open Heart</i> , 2014 , 1, e000112	3	29
44	The risk of venous thromboembolism in patients with multiple sclerosis: the Clinical Practice Research Datalink. <i>Journal of Thrombosis and Haemostasis</i> , 2014 , 12, 444-51	15.4	22
43	QT interval prolongation in users of selective serotonin reuptake inhibitors in an elderly surgical population: a cross-sectional study. <i>Journal of Clinical Psychiatry</i> , 2014 , 75, 15-21	4.6	16
42	Traceability of biopharmaceuticals in spontaneous reporting systems: a cross-sectional study in the FDA Adverse Event Reporting System (FAERS) and EudraVigilance databases. <i>Drug Safety</i> , 2013 , 36, 617-25	5.1	58
41	Incidence of adverse events among healthcare workers following H1N1 Mass immunization in Ghana: a prospective study. <i>Drug Safety</i> , 2013 , 36, 259-66	5.1	5
40	Reduced in-hospital survival rates of out-of-hospital cardiac arrest victims with obstructive pulmonary disease. <i>Resuscitation</i> , 2013 , 84, 569-74	4	16
39	Electrocardiographic characteristics of patients with chronic obstructive pulmonary disease. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2013 , 10, 62-71	2	30

38	Re: nonsteroidal anti-inflammatory drug use, chronic liver disease, and hepatocellular carcinoma. <i>Journal of the National Cancer Institute</i> , 2013 , 105, 667-8	9.7	
37	Number of patients studied prior to approval of new medicines: a database analysis. <i>PLoS Medicine</i> , 2013 , 10, e1001407	11.6	58
36	Smoking cessation strategies in patients with COPD. <i>European Respiratory Journal</i> , 2013 , 41, 727-34	13.6	34
35	Use of metformin and survival of diabetic women with breast cancer. <i>Current Drug Safety</i> , 2013 , 8, 357-63	3.4	31
34	CARING (CAnCer Risk and INsulin analogues): the association of diabetes mellitus and cancer risk with focus on possible determinants - a systematic review and a meta-analysis. <i>Current Drug Safety</i> , 2013 , 8, 296-332	1.4	40
33	Increased risk of sudden cardiac arrest in obstructive pulmonary disease: a case-control study. <i>PLoS ONE</i> , 2013 , 8, e65638	3.7	16
32	Use of insulin and insulin analogs and risk of cancer - systematic review and meta-analysis of observational studies. <i>Current Drug Safety</i> , 2013 , 8, 333-48	1.4	77
31	Use of thiazolidinediones and risk of bladder cancer: disease or drugs?. <i>Current Drug Safety</i> , 2013 , 8, 364-70	1.0	11
30	The post hoc use of randomised controlled trials to explore drug associated cancer outcomes: methodological challenges. <i>Current Drug Safety</i> , 2013 , 8, 371-8	1.4	3
29	Glucose-lowering agents and the patterns of risk for cancer: a study with the General Practice Research Database and secondary care data. <i>Diabetologia</i> , 2012 , 55, 654-65	10.3	95
28	Cardiac arrhythmias in adult patients with asthma. <i>Journal of Asthma</i> , 2012 , 49, 942-6	1.9	14
27	Safety learning from drugs of the same class: room for improvement. <i>Clinical Pharmacology and Therapeutics</i> , 2012 , 91, 872-80	6.1	6
26	Randomized controlled trials of COX-2 inhibitors: an analysis of doses used and trends over time to investigate implications for comparative safety. <i>Drug Safety</i> , 2011 , 34, 783-92	5.1	3
25	Intensive glucose control and risk of cancer in patients with type 2 diabetes. <i>Diabetologia</i> , 2011 , 54, 1608-14	1.4	29
24	A genome-wide association study of Hodgkin's lymphoma identifies new susceptibility loci at 2p16.1 (REL), 8q24.21 and 10p14 (GATA3). <i>Nature Genetics</i> , 2010 , 42, 1126-1130	36.3	158
23	Re: Late effects from radiation therapy: the hits just keep on coming. <i>Journal of the National Cancer Institute</i> , 2010 , 102, 576-7; author reply 577-8	9.7	3
22	Radiation-associated breast tumors display a distinct gene expression profile. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010 , 76, 540-7	4	49
21	Exercise echocardiography in asymptomatic survivors of childhood cancer treated with anthracyclines: a prospective follow-up study. <i>Pediatric Blood and Cancer</i> , 2010 , 54, 579-84	3	15

20	Increased risk of stroke and transient ischemic attack in 5-year survivors of Hodgkin lymphoma. <i>Journal of the National Cancer Institute</i> , 2009 , 101, 928-37	9.7	170
19	Fertility in female childhood cancer survivors. <i>Endocrine Development</i> , 2009 , 15, 135-158		13
18	Roles of radiation dose and chemotherapy in the etiology of stomach cancer as a second malignancy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009 , 75, 1420-9	4	84
17	Breast cancer risk in female survivors of Hodgkin lymphoma: lower risk after smaller radiation volumes. <i>Journal of Clinical Oncology</i> , 2009 , 27, 4239-46	2.2	261
16	Response: Malignant mesothelioma after irradiation: consistency and synergy. <i>Blood</i> , 2009 , 114, 2001-2001		
15	Malignant mesothelioma after radiation treatment for Hodgkin lymphoma. <i>Blood</i> , 2009 , 113, 3679-81	2.2	60
14	Treatment-related risk factors for premature menopause following Hodgkin lymphoma. <i>Blood</i> , 2008 , 111, 101-8	2.2	109
13	In-hospital cardiac arrest is associated with use of non-antiarrhythmic QTc-prolonging drugs. <i>British Journal of Clinical Pharmacology</i> , 2007 , 63, 216-23	3.8	78
12	Late cardiotoxicity after treatment for Hodgkin lymphoma. <i>Blood</i> , 2007 , 109, 1878-86	2.2	509
11	QTc prolongation and torsades de pointes in an elderly woman taking fluoxetine. <i>American Journal of Psychiatry</i> , 2006 , 163, 325	11.9	25
10	Prolonged QTc interval and risk of sudden cardiac death in a population of older adults. <i>Journal of the American College of Cardiology</i> , 2006 , 47, 362-7	15.1	563
9	Pharmacogenetics of drug-induced arrhythmias: a feasibility study using spontaneous adverse drug reactions reporting data. <i>Pharmacoepidemiology and Drug Safety</i> , 2006 , 15, 99-105	2.6	8
8	Hospital discharge diagnoses of ventricular arrhythmias and cardiac arrest were useful for epidemiologic research. <i>Journal of Clinical Epidemiology</i> , 2005 , 58, 1325-9	5.7	48
7	Anti-HERG activity and the risk of drug-induced arrhythmias and sudden death. <i>European Heart Journal</i> , 2005 , 26, 590-7	9.5	184
6	Predicting cardiac arrhythmias and sudden death in diabetic users of proarrhythmic drugs. <i>Diabetes Care</i> , 2005 , 28, 440-2	14.6	3
5	QTc-prolonging drugs and hospitalizations for cardiac arrhythmias. <i>American Journal of Cardiology</i> , 2003 , 91, 59-62	3	21
4	Non-sedating antihistamine drugs and cardiac arrhythmias -- biased risk estimates from spontaneous reporting systems?. <i>British Journal of Clinical Pharmacology</i> , 2002 , 53, 370-4	3.8	35
3	Use of cisapride with contraindicated drugs in The Netherlands. <i>Annals of Pharmacotherapy</i> , 2002 , 36, 338-43	2.9	12

- | | | |
|---|--|-------|
| 2 | Use of sympathomimetic drugs leads to increased risk of hospitalization for arrhythmias in patients with congestive heart failure. <i>Archives of Internal Medicine</i> , 2000 , 160, 2477-80 | 22 |
| 1 | Serum selenium, vitamin antioxidants, and cardiovascular mortality: a 9-year follow-up study in the Netherlands. <i>American Journal of Clinical Nutrition</i> , 1987 , 45, 462-8 | 7 218 |